NCT06541405View on ClinicalTrials.gov

Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2025

Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Interventions
DRUG

NK520

The number of NK520 cell infused for each dosing should be calculated base on the body weight of subject. NK520 will be administered through intravenous infusion.

Trial Locations (1)

200127

RECRUITING

Shanghai Children's Medical Center, Shanghai

All Listed Sponsors
collaborator

Shanghai Children's Medical Center

OTHER

lead

Base Therapeutics (Shanghai) Co., Ltd.

INDUSTRY